Haleon PLC — Capital/Financing Update 2025

Mar 21, 2025

6-K 1 a6962b.htm COMPLETION OF OFF-MARKET PURCHASE AND TOTAL VOTING Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2025 Issuer Direct Corporation a6962b

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

| Exhibit
Number | Description |
| --- | --- |
| 99.1 | 21
March 2025 - “Completion of off-market purchase and Total
Voting” |

99.1

Haleon plc: Completion of off-market purchase and Total Voting Rights and Capital

21 March 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that it has completed the off-market purchase of 44,155,844 ordinary shares of £0.01 each, repurchased from Pfizer Inc. for an aggregate purchase price of approximately £170 million. The purchased ordinary shares have been cancelled.

As at 21 March 2025, the total number of ordinary shares issued by Haleon is 9,039,570,075, of which 4,080,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 9,035,489,870 and this figure may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Amanda Mellor

Company Secretary

Enquiries

| Investors — Jo
Russell | + 44
7787 392441 | Media — Zo ë Bird | +44
7736 746167 |
| --- | --- | --- | --- |
| Rakesh
Patel | +44
7552 484646 | Victoria
Durman | +44 7894 505730 |
| Emma
White | +44
7823 523562 | | |
| Email: investor-relations@haleon.com | | Email: corporate.media@haleon.com | |

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information please visit www.haleon.com

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| HALEON PLC (Registrant) — /s/
Amanda Mellor | |
| --- | --- |
| Name: | Amanda
Mellor |
| Title: | Company
Secretary |